Vaccitech Newsroom
News & updates
Oxford University breakthrough on global COVID-19 vaccine
Oxford, UK - Vaccitech’s scientific founders at University of Oxford announce positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil. Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is...
Oxford coronavirus vaccine produces strong immune response in older adults
Vaccitech Ltd, a clinical-stage biopharmaceutical company developing vaccines and immunotherapies to treat and prevent infectious diseases and cancer, announces that the ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been...
Vaccitech expands management team with hires including CMO and CFO
Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing T cell vaccines and immunotherapies designed to treat and prevent infectious disease and cancer, today announces the appointment of three new senior leaders across its clinical,...
University of Oxford and Vaccitech to present at the ESMO Virtual Congress
Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that results from ADVANCE, a Phase 1/2 study in metastatic castrate resistant prostate cancer...
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across all adult age groups Vaccitech Ltd, a clinical-stage...
Vaccitech receives government grant for COVID-19 vaccine research
Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation...
Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response
Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces that Oxford University’s Jenner Institute and Oxford Vaccine Group have taken the next step towards the discovery of a...
First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
Oxford, UK – Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has dosed the first person in a Phase 1 clinical study to investigate the safety and...
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being...
Oxford COVID-19 vaccine begins human trial stage
Oxford, UK - Vaccitech announces today that its scientific founders at the Jenner Institute, University of Oxford, have begun testing a COVID-19 vaccine in human volunteers. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half...